Tesamorelin how to inject: a step-by-step protocol guide

Last updated 2026-07-25

What is the FDA-approved way to inject tesamorelin?

Tesamorelin is approved by the FDA under the brand name Egrifta (and its follow-on formulations) for one specific indication: reduction of excess visceral adipose tissue in HIV-infected patients with lipodystrophy ^[1]. The phase 3 trials that got it there used a 2 mg subcutaneous injection once daily, self-administered into the abdomen ^{[1] [2]}. That dose and route, not some other version you might read about online, is what the safety and efficacy data actually covers. The drug is a synthetic analogue of growth hormone-releasing hormone (GHRH). It works by stimulating the pituitary to release the patient's own growth hormone, rather than supplying GH directly ^{[2] [3]}. That mechanism is part of why the injection technique matters: absorption and consistency depend on getting the drug into subcutaneous fat reliably, day after day. Any use for general fat loss, bodybuilding, or anti-aging is off-label. The approval, the dosing studies, and the safety monitoring were all built around HIV-associated lipodystrophy. Nothing in the trial record speaks to outcomes in people without that diagnosis, and providers who prescribe outside the label should be doing so with that gap in evidence clearly in mind.

How do you reconstitute tesamorelin before injecting it?

Tesamorelin ships as a lyophilized (freeze-dried) powder that has to be mixed with sterile water before it can be injected. This is a two-vial system in the commercial product: one vial holds the peptide, the other holds the diluent. The general reconstitution sequence looks like this: 1. Let both vials come to room temperature if they've been refrigerated. 2. Wipe both vial tops with an alcohol swab. 3. Draw the sterile water into a syringe and inject it slowly down the inside wall of the peptide vial, not directly onto the powder. 4. Swirl gently. Don't shake. Shaking can denature the peptide and cause it to clump or lose potency. 5. Let it sit until fully clear, usually a minute or two. 6. Draw up the reconstituted solution for injection. Once mixed, tesamorelin is not shelf-stable at room temperature indefinitely. It needs refrigeration between doses. Manufacturer guidance for the approved product specifies a limited window of use after reconstitution. If the solution looks cloudy, discolored, or has visible particles, don't inject it. That's a sign of degradation or contamination, not something to push through.

Where on the body do you inject tesamorelin?

Subcutaneous injection means into the fat layer just under the skin, not into muscle. For tesamorelin, the abdomen is the site used in the phase 3 trials that supported approval ^{[1] [2]}, and it remains the standard injection site in clinical practice. Within the abdomen, rotate the exact spot. Moving a few centimeters each day, in a rough clock pattern around the navel (avoiding a 2-inch radius directly around it), reduces the odds of lipohypertrophy, the lumpy fat buildup that comes from injecting the same spot over and over. This is the same rotation logic used with insulin injections, and it applies just as much here. People sometimes ask about the thigh or upper arm as alternate sites. There isn't trial data on tesamorelin absorption from those locations. Sticking with the abdomen, as studied, is the more defensible choice if you want your results to track what the trials actually showed.

What injection technique actually works, step by step?

Here's the practical sequence, once the dose is drawn up. 1. Wash hands. Wipe the injection site with an alcohol swab and let it air dry for a few seconds (injecting through wet alcohol stings). 2. Pinch a fold of abdominal skin between two fingers to lift the fat layer away from muscle. 3. Insert the needle at a 45 to 90 degree angle, depending on how much subcutaneous fat is at that spot and the needle length being used. Thinner people generally do better with a shallower angle. 4. Push the plunger slowly and steadily. Fast injection increases discomfort and can cause the solution to pool and leak back out. 5. Withdraw the needle and press (don't rub) a clean gauze or cotton ball over the site for a few seconds. 6. Dispose of the needle in a sharps container immediately. Never recap a used needle. A new needle and syringe every time is non-negotiable, both for infection control and because needles dull after a single use, which makes the injection more painful than it needs to be. One detail people underestimate: injection speed. Growth hormone-releasing hormone analogues like tesamorelin are peptides, and pushing them in too fast doesn't make the dose work faster. It just makes the site sting more and raises the chance of local irritation.

When during the day should tesamorelin be injected?

The phase 3 program dosed tesamorelin once daily ^{[1] [2]}, and most clinical guidance recommends taking it at bedtime, roughly mirroring the body's natural nighttime pulse of growth hormone release. This isn't arbitrary. GHRH analogues work with the pituitary's own rhythm, and nighttime dosing lines up with when endogenous GH secretion is naturally highest. Consistency matters more than the exact clock time. Injecting around the same time each night keeps drug exposure steady, which is closer to how the pharmacokinetic studies characterized the drug's absorption and clearance in both HIV-positive patients and healthy subjects ^[4]. Missing the routine occasionally isn't a crisis. But a dose taken at wildly different times day to day makes it harder to know what's actually driving any change you see (or don't see) in your midsection. Avoid injecting right before a workout or right after eating a heavy meal if you can help it. Neither has been shown in trials to matter for tesamorelin specifically, but both introduce noise into how you feel afterward and can make it harder to tell injection-site reactions from unrelated symptoms. See our full timeline breakdown in how long tesamorelin takes to work for how consistent dosing connects to the trial endpoints.

What if you miss a dose or inject incorrectly?

If a dose is missed, the standard approach with once-daily peptide injections is to skip it and resume the normal schedule the next day, rather than doubling up. Doubling a dose to "catch up" increases the risk of side effects without any evidence it improves outcomes, since the trials that established safety and efficacy used a fixed once-daily schedule ^[1]. If you inject into muscle instead of fat by accident, expect faster absorption and possibly more discomfort at the site, but it's not usually a medical emergency. Watch for unusual swelling, redness that spreads, or fever, which would be reasons to contact the prescribing provider. If you notice blood in the syringe after inserting the needle (meaning you likely hit a small blood vessel), withdraw, apply pressure, and re-inject at a different spot with a fresh needle. Don't push the dose through a bloody draw.

What are the common injection-site side effects?

In the pooled phase 3 trial data, injection-site reactions were among the most frequently reported adverse events with tesamorelin, including erythema (redness), pruritus (itching), and pain at the injection site . These were generally described as mild to moderate rather than serious. But they were common enough to be a real part of the drug's tolerability profile, not a rare footnote. Rotating injection sites, using a fresh needle each time, and not reusing the same small patch of skin day after day meaningfully reduces the rate of localized skin reactions like lipohypertrophy or persistent redness. If a site stays red, warm, and tender for more than a couple of days, or if you develop a hard nodule that doesn't resolve, that's worth flagging to the prescribing clinician rather than working around it. Beyond the injection site itself, the broader adverse event profile in the trials included joint-related symptoms, muscle pain, and, notably, a numeric increase in cases classified as impaired glucose tolerance or new-onset diabetes relative to placebo ^[1] . Injection technique doesn't affect those systemic risks. They're a property of the drug's mechanism, and they're why treatment is meant to happen under medical supervision with periodic monitoring, not as a self-directed routine.

How does tesamorelin's injection protocol compare to other GH-axis peptides?

Recent reviews of peptide therapy in sports medicine and orthopaedics have started cataloguing injectable GH-axis peptides side by side, since prescribers and patients increasingly ask how they stack up on practical grounds like dosing frequency and administration burden ^{[5] [6]}. Tesamorelin's once-daily subcutaneous abdominal injection, at a fixed 2 mg dose per the approved labeling studied in trials ^[1], is relatively simple compared to some multi-peptide stacks that require different injection times or sites for different compounds. | Feature | Tesamorelin (Egrifta) |

Does injection technique affect how well tesamorelin works?

There's no published trial specifically isolating injection technique as a variable in tesamorelin's efficacy, so anything said here is inference from general pharmacology plus the drug's known pharmacokinetics, not a direct study finding. What the population pharmacokinetic analysis does show is that tesamorelin's absorption and clearance were characterized consistently across HIV-infected patients and healthy subjects using the standard subcutaneous route ^[4], which is the basis for the labeled instructions. Injecting into muscle instead of fat likely changes absorption speed, since subcutaneous tissue and muscle have different blood flow and diffusion characteristics. Injecting into scarred or heavily lipohypertrophied tissue can slow or make absorption erratic, which is one more reason site rotation matters beyond just cosmetic skin concerns. Beyond that, there's no evidence that pinching versus not pinching the skin, or the exact needle gauge, meaningfully changes outcomes for tesamorelin specifically. Reasonable technique, consistent site rotation, and dosing on schedule are what the trial protocols actually modeled ^{[1] [2]}. Deviating wildly from that, in either direction, moves you away from the conditions the evidence was generated under.

How long before you see results from tesamorelin injections?

Visceral fat reduction in the phase 3 trials was measured at 26 weeks (about 6 months) using CT scan quantification, and the meaningful reductions in visceral adipose tissue seen in the tesamorelin groups versus placebo were reported at that endpoint ^[1] . That's the timeframe the approval is actually based on, not weeks. Some downstream effects took even longer to show up in secondary analyses. A related trial on non-alcoholic fatty liver disease in HIV patients tracked outcomes over a year, finding tesamorelin reduced hepatic fat fraction compared to placebo at that longer horizon . Improvements in liver enzymes were also linked specifically to the degree of visceral fat reduction achieved, not simply to being on the drug . For a fuller breakdown of the trial timelines and what changed at each measured interval, see how long does tesamorelin take to work. The short version: this is a months-long protocol, not a weeks-long one, and injection technique doesn't shortcut that.

How do you know your tesamorelin is legitimate before you inject it?

Tesamorelin is a peptide, and peptides are a known target for substandard or mislabeled products sold outside legitimate pharmacy channels. Since the drug requires reconstitution and precise dosing, starting with a product that has verified potency and purity matters more than it might for a stable oral tablet. Bulk tesamorelin used in outsourcing facility or pharmacy compounding is governed by FDA's bulk drug substance rules under section 503A of the Federal Food, Drug, and Cosmetic Act, and the compounding regulations set out at 21 CFR 216.23 and 216.24 specify what qualifies for the applicable bulks lists ^{[7] [8] [9] [10]}. Compounded versions exist because the FDA-approved product doesn't cover every prescribed use, but compounded tesamorelin is not the same as the trial-tested Egrifta formulation, and quality can vary by compounder. For a detailed walk-through of what a certificate of analysis should show and how to read one before you trust a vial, see tesamorelin certificate of analysis explained. At minimum, a legitimate product should come with third-party purity testing and clear labeling of concentration per vial, because getting the reconstitution math wrong is one of the most common real-world dosing errors. At Tesamorelin Co, we point readers toward the provider-reviewed route: a prescriber who confirms the indication is appropriate, and a fulfilling pharmacy partner who can document sourcing and testing. We don't compound or manufacture anything ourselves. The point is knowing where your vial actually came from before you draw it up.

Who should not attempt to self-inject tesamorelin?

Tesamorelin carries labeled warnings against use in patients with active malignancy, and it requires caution in anyone with a history of pituitary disease, diabetes, or fluid retention issues, since GHRH stimulation affects glucose metabolism and can worsen edema ^[1] . Anyone with these conditions needs a prescriber actively managing the decision to use it at all, more than the injection mechanics. Pregnant or breastfeeding patients weren't part of the phase 3 trial populations, and there's no safety data to lean on there. People new to any subcutaneous injection, regardless of the drug, sometimes benefit from a first supervised injection with a nurse or pharmacist walking through it live, rather than learning entirely from written instructions or video. Finally, anyone considering tesamorelin for a reason outside HIV-associated lipodystrophy, the only FDA-approved indication ^[1], should understand they're in off-label territory where the injection protocol may be extrapolated from trial data that wasn't designed to answer their actual question.

Frequently asked questions

What is the standard tesamorelin injection dose?

The phase 3 trials that led to FDA approval used 2 mg subcutaneously once daily for HIV-associated lipodystrophy ^[1][2]. That's the only dose and schedule backed by placebo-controlled trial data. Any other dosing schedule you encounter outside a prescriber's guidance isn't supported by the approved label or the trial data.

Can you inject tesamorelin into your thigh instead of your abdomen?

The trials that established tesamorelin's safety and efficacy used abdominal subcutaneous injection ^[1][2]. There's no published trial data on absorption from the thigh or arm, so sticking with the abdomen, as studied, keeps you aligned with the evidence base rather than guessing at an untested site.

How do you reconstitute tesamorelin powder?

Inject sterile water slowly down the vial wall (not directly onto the powder), swirl gently without shaking, and wait until the solution is clear before drawing it up. Cloudy or particulate solution should not be injected. Reconstituted tesamorelin needs refrigeration and has a limited use window, per manufacturer guidance for the approved product.

What needle size is used for tesamorelin injections?

Subcutaneous injections typically use a short, fine-gauge needle (commonly in the 29 to 31 gauge range with a short needle length), similar to what's used for insulin. The exact needle supplied depends on the pharmacy dispensing the product; follow the specific instructions that come with your prescription.

Does tesamorelin injection hurt?

Injection-site pain, redness, and itching were among the most commonly reported adverse events in the phase 3 trials ^[24]. Most reactions were mild to moderate. Slow, steady injection technique and site rotation reduce discomfort; persistent pain or swelling beyond a couple of days should be reported to your prescriber.

What time of day should you inject tesamorelin?

Most clinical guidance recommends bedtime dosing, since it roughly mirrors the body's natural nighttime pulse of growth hormone release and matches the once-daily schedule used in the phase 3 trials ^[1][2]. Consistency in timing day to day matters more than the exact clock hour chosen.

What happens if you miss a dose of tesamorelin?

Skip the missed dose and resume your normal schedule the next day. Don't double up to compensate. The trials that established tesamorelin's safety profile used a fixed once-daily schedule ^[1], and doubling a dose introduces risk without any evidence of added benefit.

Is tesamorelin FDA-approved for general fat loss?

No. The only FDA-approved indication is reduction of excess visceral adipose tissue in HIV-infected patients with lipodystrophy ^[1]. Use for general fat loss, bodybuilding, or anti-aging purposes is off-label and isn't supported by the phase 3 trial data, which was conducted exclusively in that patient population.

Can you reuse a tesamorelin needle or syringe?

No. Use a fresh, sterile needle and syringe for every injection. Reused needles dull quickly, which increases pain and tissue trauma, and reuse raises infection risk. Dispose of used needles immediately in a sharps container; never recap a used needle.

How long does it take to see visceral fat reduction from tesamorelin?

The phase 3 trials measured visceral adipose tissue by CT scan at 26 weeks (about 6 months), which is the timepoint the FDA approval is based on ^[1][20]. Related trials tracking liver fat outcomes followed patients for up to a year to detect further changes ^[19]. See our full breakdown of how long tesamorelin takes to work for the week-by-week detail.

What are the injection-site side effects of tesamorelin?

Pooled phase 3 data reported erythema (redness), pruritus (itching), and pain at the injection site as common adverse events, generally mild to moderate ^[24]. Rotating sites and using fresh needles each time reduces localized skin reactions like lipohypertrophy (fatty lumps from repeated injection at the same spot).

Do you need a prescription to get tesamorelin?

Yes. Tesamorelin (Egrifta) is an FDA-approved prescription drug, and compounded versions are also dispensed only through licensed pharmacies under a prescriber's order, governed by pharmacy compounding statute 21 U.S.C. 353a ^[8]. There's no legitimate over-the-counter route. If you're evaluating a vial's legitimacy, our guide to reading a tesamorelin certificate of analysis covers what to check before you draw up a dose.

Can tesamorelin be injected into muscle instead of subcutaneous fat?

The approved route is subcutaneous, into abdominal fat, not intramuscular ^[1][2]. Accidentally hitting muscle likely changes absorption speed and can increase discomfort, but it isn't typically a medical emergency. Watch for spreading redness, fever, or unusual swelling, and contact your prescriber if those occur.

Sources

1. PubMed, Tesamorelin (PMID 31644039): Tesamorelin is FDA-approved for reduction of excess visceral adipose tissue in HIV-infected patients with lipodystrophy, using a 2 mg subcutaneous once-daily dose studied in phase 3 trials.
2. PubMed, Tesamorelin (PMID 21283099): Tesamorelin's mechanism as a GHRH analogue and its route/dose in the trials leading to approval.
3. PubMed, Tesamorelin, a human growth hormone releasing factor analogue (PMID 19243281): Tesamorelin stimulates the pituitary to release endogenous growth hormone rather than supplying GH directly.
4. PubMed, Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions (PMID 41490200): Recent orthopaedic peptide reviews catalogue injectable GH-axis peptides and compare administration approaches.
5. PubMed, Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians (PMID 41476424): Many injectable peptides discussed in sports medicine literature are unapproved with thinner human safety data than tesamorelin.
6. eCFR, 21 CFR 216.23 (503A Bulks List): Defines what bulk drug substances qualify for compounding under section 503A.
7. eCFR, 21 CFR 216.24 (503B Bulks List): Defines what bulk drug substances qualify for outsourcing facility compounding under section 503B.
8. Cornell Law, 21 U.S.C. 353a (pharmacy compounding): Pharmacy compounding of drugs including tesamorelin is governed by federal statute requiring a valid prescription.
9. FDA, Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act: FDA maintains the regulatory framework determining which bulk substances can be compounded under 503A.
10. PubMed, Population pharmacokinetic analysis of tesamorelin (PMID 25358450): Tesamorelin's absorption and clearance were characterized via the standard subcutaneous route across HIV-infected patients and healthy subjects.
11. PubMed, Visceral fat reduction with tesamorelin is associated with improved liver enzymes in HIV (PMID 28832410): Improvements in liver enzymes were linked to the degree of visceral fat reduction achieved, not merely to drug exposure.
12. PubMed, Effects of tesamorelin on non-alcoholic fatty liver disease in HIV (PMID 31611038): A randomized trial tracked hepatic fat fraction reduction with tesamorelin over roughly a year.
13. PubMed, Effects of tesamorelin (TH9507) in HIV-infected patients with excess abdominal fat: pooled phase 3 analysis (PMID 20554713): Phase 3 trials measured visceral adipose tissue reduction by CT scan at 26 weeks.